CoapTech News

CoapTech European Patent Release

Jul 18, 2018 6:28:06 PM / by Jack Kent, MBA, MPH

CoapTech Granted European Patent for PUMA Technology

United States Patent Application Currently Under Review

BALTIMORE (June 13, 2018) – CoapTech, an early-stage medical device company developing its PUMA platform technology, was granted a patent for its core intellectual property by the European Patent Office. This patent is valid in 40 European nations.

“This patent is a major step forward for CoapTech as we continue developing uses for the PUMA System and plan to offer our devices internationally,” said CoapTech co-founder Howard Carolan. “This technology can increase patient safety and improve the overall care experience while driving down medical costs. This will be attractive to the medical community around the world.”

PUMA (Point-of-care Ultrasound Magnet Aligned) is a platform technology that allows clinicians to visualize critical tissue around hollow organs, enabling minimally-invasive procedures guided by ultrasound to maximize patient safety. PUMA uniquely leverages rare-earth magnets for positioning and placement. The European Patent Office granted a patent for the company’s novel class of medical catheters; the technology is patent pending in the United States.

The first use of the technology in the field will be a medical device that non-surgical providers can use to safely perform feeding tube placement at the bedside through a procedure termed PUG (Percutaneous Ultrasound Gastrostomy). PUG is minimally invasive and more cost-effective compared to traditional feeding tube placement procedures which can require specialists, greater levels of sedation, and use of operating rooms.


About CoapTech

CoapTech, founded by Steve Tropello, MD, MS and Howard Carolan, MPH, MBA, is an early stage medical device company based in Baltimore, Md. that owns the PUMA platform. PUMA (Point-of-care Ultrasound Magnet Aligned) seeks to disrupt multiple medical procedures, substantially reducing costs while improving patient safety and experience. The platform’s first manifestation is PUMA-G for gastrostomies, which has a streamlined regulatory pathway based on FDA presubmission feedback. The company expects to receive FDA clearance via the standard 510(k) pathway without clinical studies. CoapTech was named 2018 Maryland Incubator Company of the Year for Best Medical Device Company.



Jack Kent, MBA, MPH

Written by Jack Kent, MBA, MPH

Mr. Kent is an experienced medical device executive with significant prior work leading companies in efforts to deliver novel technology and positively impact patient care. In his most recent endeavor, Mr. Kent directed 6 product development projects from concept to delivery. These products are now available in the United States, the European Union, and Canada. His team successfully navigated FDA reviews, CE Mark reviews, FDA inspections, and ISO 13485 Notified Body audits – among other activities. Mr. Kent has worked with diverse product types, ranging in specialty (e.g., IR, GI, ORTH), use (therapeutic/diagnostic), and other characteristics (e.g., electrical, single-use vs. reusable, sterile/nonsterile, software).